Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966296 | 0.86 | MEN1 (0.48) | MEN1KMT2A | |
| SCHEMBL9705177 | 0.85 | MEN1 (0.54) | MEN1KMT2ASLC6A3NPC1RAB9A | |
| SCHEMBL7622057 | 0.85 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL9308239 | 0.83 | MEN1 (0.49) | MEN1KMT2ANPC1RAB9AKDM4C | |
| SCHEMBL9705239 | 0.83 | MEN1 (0.49) | MEN1KMT2ANPC1RAB9AKDM4C | |
| SCHEMBL22070786 | 0.82 | KMT2A (0.45) | MEN1KMT2ASLC6A3NPC1RAB9A | |
| SCHEMBL22070848 | 0.82 | MEN1 (0.52) | MEN1KMT2ASLC6A3NPC1RAB9A | |
| SCHEMBL28454991 | 0.82 | MEN1 (0.44) | MEN1KMT2ASLC6A3KDM4CADORA3 | |
| SCHEMBL11138560 | 0.81 | MEN1 (0.46) | MEN1KMT2A | |
| SCHEMBL11541470 | 0.78 | MEN1 (0.45) | MEN1KMT2ANPC1RAB9AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-5302370-A | Form complexes with rhenium and technetium | INSTITUT FUR DIAGNOSTIKFORSCHUNG GMBH (DE) | 1994-04-12 | — | — | US | disclosed |
| EP-0502595-A2 | Amide chelates, their metal complexes and their use in diagnosis and therapy | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN (DE) | 1992-09-09 | — | — | EP | disclosed |
| EP-0417870-A2 | Chelates for complexation of radioactive isotopes, their metal complexes and their use in diagnosis and therapy | INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN (DE) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | MEN1 1909/4885KMT2A 1910/4885SLC6A3 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.